Redx Pharma (LSE:REDX) EBIT per Share : £-0.09 (TTM As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Redx Pharma EBIT per Share?

Redx Pharma's EBIT per Share for the six months ended in Sep. 2023 was £-0.03. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.09.

During the past 3 years, the average EBIT per Share Growth Rate was -23.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was -5.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Redx Pharma's EBIT per Share or its related term are showing as below:

LSE:REDX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -86.4 Med: -3.4 Max: 32.3
Current: -23.8

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Redx Pharma was 32.30% per year. The lowest was -86.40% per year. And the median was -3.40% per year.

LSE:REDX's 3-Year EBIT Growth Rate is ranked worse than
77.33% of 1301 companies
in the Biotechnology industry
Industry Median: 3.4 vs LSE:REDX: -23.80

Redx Pharma's EBIT for the six months ended in Sep. 2023 was £-11.24 Mil.

Redx Pharma EBIT per Share Historical Data

The historical data trend for Redx Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redx Pharma EBIT per Share Chart

Redx Pharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EBIT per Share

Get a 7-Day Free Trial

-0.05

-0.08

-0.06

-0.09

Redx Pharma Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EBIT per Share	Get a 7-Day Free Trial															-0.03	-0.03	-0.02	-0.06	-0.03

Redx Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Redx Pharma's EBIT per Share for the fiscal year that ended in Sep. 2023 is calculated as

	EBIT per Share		(A: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-30.987	/	334.911
=	-0.09

Redx Pharma's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

	EBIT per Share		(Q: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-11.237	/	334.911
=	-0.03

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.09

Redx Pharma (LSE:REDX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Redx Pharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Redx Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Redx Pharma (LSE:REDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Redx Pharma PLC (LSE:REDX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Block 33, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG

Website

https://www.redxpharma.com

Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration and Research and preclinical development services. Redx is a clinical-stage biotechnology company focused on the discovery & development of novel, small-molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis.

Redx Pharma (LSE:REDX) Headlines

No Headlines